KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Profit After Tax (2016 - 2025)

Sarepta Therapeutics has reported Profit After Tax over the past 15 years, most recently at -$412.2 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$412.2 million for Q4 2025, down 359.18% from a year ago — trailing twelve months through Dec 2025 was -$713.4 million (down 403.27% YoY), and the annual figure for FY2025 was -$713.4 million, down 403.27%.
  • Profit After Tax for Q4 2025 was -$412.2 million at Sarepta Therapeutics, down from -$50.6 million in the prior quarter.
  • Over the last five years, Profit After Tax for SRPT hit a ceiling of $196.9 million in Q2 2025 and a floor of -$516.8 million in Q1 2023.
  • Median Profit After Tax over the past 5 years was -$66.0 million (2021), compared with a mean of -$106.8 million.
  • Peak annual rise in Profit After Tax hit 2947.86% in 2025, while the deepest fall reached 1338.98% in 2025.
  • Sarepta Therapeutics' Profit After Tax stood at -$122.0 million in 2021, then rose by 10.44% to -$109.2 million in 2022, then soared by 141.79% to $45.7 million in 2023, then skyrocketed by 248.37% to $159.0 million in 2024, then crashed by 359.18% to -$412.2 million in 2025.
  • The last three reported values for Profit After Tax were -$412.2 million (Q4 2025), -$50.6 million (Q3 2025), and $196.9 million (Q2 2025) per Business Quant data.